Intelligent Ultrasnd - PDMR/PCA Dealing
23/03/2023 16:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230323:nRSW0694Ua&default-theme=true
RNS Number : 0694U Intelligent Ultrasound Group PLC 23 March 2023
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company" or the "Group")
PDMR/PCA Dealing
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces the following director & person closely associated
share transactions.
The Company announces that Ian Whittaker, the Chief Commercial Officer and a
Person Discharging Managerial Responsibilities of the Company ("PDMR"),
transferred 81,000 Ordinary Shares in the Company for nil consideration on 23
March 2023 to a nominee account of which his wife is the beneficial owner.
Following these transactions, Ian Whittaker's interest in Ordinary Shares and
that of his persons closely associated remains unchanged at 532,253 Ordinary
Shares of 1p representing 0.16% of the total issued share capital of the
Company.
This notification relates to transactions notified in accordance with the
Market Abuse Regulation, further details below:
NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Ian Whittaker
2 Reason for the notification
a) Position/status Chief Commercial Officer, PDMR
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Full name of the entity Intelligent Ultrasound Group plc
b) Legal entity identifier code 213800K4ZVWL4ZYQAZ70
4 Details of the transaction(s)
a) Description of the financial instrument, type of instrument Ordinary shares in Intelligent Ultrasound plc with a nominal value of 1 pence
each
b) Identification Code GB00BN791Q39
c) Nature of the transaction Transfer to a nominee account
d) Currency GBP - British pound
e) Price(s) and Volume(s) Nil£ and 81,000 Ordinary Shares
f) Aggregated information N/A
- Price
- Volume
- Total
g) Date of transaction 23 March 2023
h) Place of transaction London Stock Exchange
NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Sarah Whittaker
2 Reason for the notification
a) Position/status PCA, Wife of Chief Operating Officer
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Full name of the entity Intelligent Ultrasound Group plc
b) Legal entity identifier code 213800K4ZVWL4ZYQAZ70
4 Details of the transaction(s)
a) Description of the financial instrument, type of instrument Ordinary shares in Intelligent Ultrasound plc with a nominal value of 1 pence
each
b) Identification Code GB00BN791Q39
c) Nature of the transaction Receipt of shares to a nominee account
d) Currency GBP - British pound
e) Price(s) and Volume(s) Nil£ and 81,000 Ordinary Shares
f) Aggregated information N/A
- Price
- Volume
- Total
g) Date of transaction 23 March 2023
h) Place of transaction London Stock Exchange
Intelligent Ultrasound Group plc www.intelligentultrasound.com (http://www.intelligentultrasound.com)
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor and broker Tel: +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael Johnson / Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
(mailto:intelligentultrasound@walbrookpr.com)
Anna Dunphy Mob: +44 (0)7876 741 001
ABOUT INTELLIGENT ULTRASOUND GROUP
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,450 simulators have been sold to over 700 medical
institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis
technology. Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson Expert
22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound image interpretation by providing the user with real-time AI-based
anatomy highlighting for a range of ultrasound guided regional anesthesia
procedures; and NeedleTrainer that teaches real-time ultrasound-guided
needling and incorporates ScanNav Anatomy PNB.
www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBLGDXXSDDGXX